Trial Profile
Prospective study for usefulness of plasma DNA on prediction of third generation EGFR tyrosine kinase inhibitors
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2020
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms S-PLAT study
- 31 May 2020 Results (N=57), assessing role of T790M detection can predict a good therapeutic effect, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 10 Sep 2019 Results assessing the impact of T790M level on osimertinib treatment efficacy, presented at the 20th World Conference on Lung Cancer
- 04 Feb 2019 Status changed from recruiting to active, no longer recruiting.